findmyKOL
Clinical trialNCT05696782RecruitingPhase 2Interventional

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

SponsorWake Forest University Health SciencesEnrollment28Nonsmall Cell Lung Cancer Stage IIINonsmall Cell Lung Cancer, Stage IIUnresectable Non-Small Cell Lung Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Wake Forest Baptist Comprehensive Cancer Center

    Winston-Salem, North Carolina, United States

    Thomas Lycan, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 Jul 2023
Primary completion
28 Feb 2027
Completion
30 Apr 2027
Last update posted
6 Jul 2026
Registered enrollment
28
Registry id
NCT05696782
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.